doi: 10.1021/acsomega.3c04345 42 LiuZDuanJ-HSongY-MMaJWangF-DLuXet al
Human sarcopenia evidence was not identified
Pinnacle Peptides is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act
Treat blend-specific claims as inference from the component data, not proven blend outcomes
Pharmaceutical intermediate synthesis
5-Amino-1MQ was developed as a pharmacological tool to inhibit NNMT activity, and preclinical studies have demonstrated that oral administration of 5-Amino-1MQ to obese rodents produces dose-dependent reductions in body weight and fat mass, improvements in glucose metabolism and insulin sensitivity, and increases in energy expenditure - remarkably, these effects occur without changes in food intake, indicating that 5-Amino-1MQ works through metabolic enhancement and increased caloric burn rather than appetite suppression